Abbott rises after positive Amulet 360 study results

What happened

Abbott (ABT) rose 3.7% on November 2, 2026, after positive one-year VERITAS results for its Amulet 360 left atrial appendage occluder were presented and published. The company presented the data at Transcatheter Cardiovascular Therapeutics and published it in JACC: Cardiovascular Interventions, and the news was reported by Benzinga and PRNewsWire. The stock opened 0.6% above the previous close and closed at $110.16. The move came while the S&P 500 fell 0.5% on the day.

How big was the move

The stock’s 3.7% rise was 2.6 times a typical daily move for this stock, marking a large session relative to its normal swings. Trading volume was 0.9 times its 20-day average, so the price change came on slightly below-average volume. Over the last five sessions the stock rose 5.0%, outperforming the Healthcare sector median by 5.4 percentage points as the sector fell 1.6% on the day. The computed interpretation flags this as a large, mostly company-specific move and links it to the clinical data release because the company news is the likely driver.

The technical picture

The stock sat above short- and long-term averages: 7.1% above its 20-day moving average, 5.7% above its 50-day moving average and 8.4% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 8 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) was 67, inside a neutral range, and the share price remained 16.6% below its 52-week high.

Momentum showed a one-month rise of 13.0% and a three-month rise of 4.5%, while the one-year change was a fall of 11.6%, 22.2 percentage points behind the S&P 500. Volatility measured 23% annualized over 60 days, higher than 56% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, revenue was $48.23 billion, which grew 10.0% from a year earlier and followed growth of 8.1% one quarter earlier. Diluted earnings per share were $2.70, with earnings per share growth from a year earlier falling 66.2%. Gross margin improved to 57.1% from 54.0% a year earlier, while operating margin was 15.2% compared with 17.8% a year earlier. Return on invested capital was 5.6% and share count over one year decreased by 0.6%.

Valuation multiples show the stock at 40.8 times trailing earnings, the highest reading of the past five years versus a five-year median of 30.1 times earnings. Price to forward earnings was 20.0 times expected earnings. PromtFinance scores place Abbott’s Quality at 93 (Exceptional) and Stability at 100 (Exceptional), while Growth scored 33 (Weak) and Revisions scored 12 (Very weak).

Earnings and analyst expectations

Abbott’s last report was on October 21, 2026, when earnings per share were $1.42 against $1.42 expected, 0.0% above estimates. The company has recorded zero consecutive quarters beating estimates and the average surprise over the last four reports was 0.8% above estimates. The typical two-day reaction after recent reports was that the stock fell 1.9%. The next scheduled report is January 28, 2027.

Analysts covering the stock total 43, with 77% rating the stock Buy or Strong Buy and a consensus rating of Buy. The consensus price target is $121.36, 10.2% above the closing price.

What to watch

• January 28, 2027: next earnings report date
• VERITAS one-year results published in JACC: Cardiovascular Interventions and presented at Transcatheter Cardiovascular Therapeutics, showing high rates of LAA closure and a low incidence of stroke (reported by Benzinga and PRNewsWire)
• TECTONIC trial 30-day outcomes for SonicForce Coronary Intravascular Lithotripsy system, reporting strong outcomes and high procedural success (reported by GuruFocus and PRNewsWire)
• Consensus price target of $121.36, 10.2% above the closing price
• The stock’s valuation at 40.8 times trailing earnings, the highest of the past five years